The Merlin Test (CP-GEP) Accurately Stratifies Cutaneous Melanoma Patients as Low Risk or High Risk for Sentinel Lymph Node Metastases Impacting Clinical Decision Making
Merlin test (CP-GEP) [1] successfully stratifies T1a melanoma patients considered for sentinel lymph node biopsy (SLNB) by their care providers, reducing SLNB surgeries by 87.6% with a negative predictive value (NPV) of 98.5%.
Merlin test (CP-GEP) identifies high-risk T1a melanoma patients for SLNB surgery, even those who might be missed due to the absence of conventional adverse features, offering a more precise and individualized approach to managing early-stage melanoma.
